{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:51:34Z","timestamp":1760575894521,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jfma.2023.08.023","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:07:58Z","timestamp":1693667278000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9488-6185","authenticated-orcid":false,"given":"Ching-Chu","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":false,"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-974X","authenticated-orcid":false,"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4949-393X","authenticated-orcid":false,"given":"Wei-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-084X","authenticated-orcid":false,"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Yen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jfma.2023.08.023_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.jfma.2023.08.023_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jfma.2023.08.023_bib3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00001432-200206000-00008","article-title":"The interferon antiviral response: from viral invasion to evasion","volume":"15","author":"Grandvaux","year":"2002","journal-title":"Curr Opin Infect Dis"},{"issue":"5","key":"10.1016\/j.jfma.2023.08.023_bib4","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/bcp.15176","article-title":"Novel long-acting ropeginterferon alfa-2b: pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial","volume":"88","author":"Huang","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jfma.2023.08.023_bib5","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1007\/s12325-021-01863-y","article-title":"Pharmacokinetics and pharmacodynamics of novel long-acting ropeginterferon alpha-2b in healthy Chinese subjects","volume":"38","author":"Huang","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.jfma.2023.08.023_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","article-title":"Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration","volume":"41","author":"Miyachi","year":"2021","journal-title":"Clin Drug Invest"},{"issue":"1","key":"10.1016\/j.jfma.2023.08.023_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (Pegasys)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expr Purif"},{"issue":"4","key":"10.1016\/j.jfma.2023.08.023_bib8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"10.1016\/j.jfma.2023.08.023_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jgh3.12613","article-title":"Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: pharmacokinetics, safety, and preliminary efficacy","volume":"5","author":"Lin","year":"2021","journal-title":"JGH Open"},{"issue":"3","key":"10.1016\/j.jfma.2023.08.023_bib10","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jfma.2020.09.018","article-title":"Ropeginterferon alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C","volume":"120","author":"Hsu","year":"2021","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"10.1016\/j.jfma.2023.08.023_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","article-title":"Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B","volume":"14","author":"Huang","year":"2020","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.jfma.2023.08.023_bib12","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"year":"2019","series-title":"Package Insert: PEGINTRON\u00ae (peginterferon alfa-2b)","key":"10.1016\/j.jfma.2023.08.023_bib13"},{"year":"2002","series-title":"US FDA Package Insert: PEGASYS\u00ae (peginterferon alfa-2a)","key":"10.1016\/j.jfma.2023.08.023_bib14"},{"year":"2021","series-title":"FDA approves treatment for rare blood disease","key":"10.1016\/j.jfma.2023.08.023_bib15"},{"year":"2021","series-title":"US FDA Package Insert: BESREMI\u00ae (ropeginterferon alpha-2b-njft)","key":"10.1016\/j.jfma.2023.08.023_bib16"},{"issue":"27","key":"10.1016\/j.jfma.2023.08.023_bib17","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.2217\/fon-2022-0596","article-title":"SurPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.jfma.2023.08.023_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/jgh3.12825","article-title":"A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C","volume":"6","author":"Chen","year":"2022","journal-title":"JGH Open"},{"issue":"6","key":"10.1016\/j.jfma.2023.08.023_bib19","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/v14061128","article-title":"Novel pegylated interferon for the treatment of chronic viral hepatitis","volume":"14","author":"Huang","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.jfma.2023.08.023_bib20","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s12325-021-01998-y","article-title":"Clinical experience with ropeginterferon Alfa-2b in the off-label use for the treatment of COVID-19 patients in Taiwan","volume":"39","author":"Chen","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jfma.2023.08.023_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.22070","article-title":"Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop","volume":"47","author":"Chung","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2023.08.023_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: what we know now and what remains to be researched","volume":"3","author":"Suk-Fong Lok","year":"2019","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.jfma.2023.08.023_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jfma.2023.08.023_bib24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jfma.2023.08.023_bib25","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3390\/v13102096","article-title":"The role of RASs\/RVs in the current management of HCV","volume":"13","author":"Malandris","year":"2021","journal-title":"Viruses"},{"journal-title":"SmPC (Summary of Product Characteristics): HEPCLUDEX 2 mg Powder for Solution for Injection","article-title":"Ireland UC","year":"2020","key":"10.1016\/j.jfma.2023.08.023_bib26"},{"key":"10.1016\/j.jfma.2023.08.023_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1109866","article-title":"An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: an overview of previous and ongoing studies with perspectives on the future","volume":"13","author":"Qin","year":"2023","journal-title":"Front Oncol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623003376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664623003376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:51:27Z","timestamp":1760539887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664623003376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0929664623003376"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2023.08.023","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2023.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}